These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7535186)

  • 1. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
    Figg WD; Thibault A; Cooper MR; Reid R; Headlee D; Dawson N; Kohler DR; Reed E; Sartor O
    Cancer; 1995 Apr; 75(8):2159-64. PubMed ID: 7535186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
    Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatuline Autogel: an extended release lanreotide formulation.
    Lightman S
    Hosp Med; 2002 Mar; 63(3):162-5. PubMed ID: 11933820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
    Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M
    Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
    Canobbio L; Cannata D; Miglietta L; Boccardo F
    Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
    Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
    Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
    J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
    Liu G; Kelly WK; Wilding G; Leopold L; Brill K; Somer B
    Clin Cancer Res; 2009 May; 15(9):3172-6. PubMed ID: 19366825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
    Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
    Ann N Y Acad Sci; 2004 Dec; 1028():361-74. PubMed ID: 15650261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiproliferative effects of the somatostatin analogue somatuline in a rabbit model of traction retinal detachment.
    Baudouin C; Imbert F; Ettaiche M; Gastaud P
    Fundam Clin Pharmacol; 1995; 9(4):357-65. PubMed ID: 8566935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
    Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
    Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide in advanced prostatic cancer relapsing under hormonal treatment.
    Verhelst J; De Longueville M; Ongena P; Denis L; Mahler C
    Acta Urol Belg; 1994 Apr; 62(1):83-8. PubMed ID: 7515212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
    Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
    Latif T; Wood L; Connell C; Smith DC; Vaughn D; Lebwohl D; Peereboom D
    Invest New Drugs; 2005 Jan; 23(1):79-84. PubMed ID: 15528984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
    Kaprin AD; Gafanov PA; Fastovets SV
    Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.